Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Am J Cardiovasc Drugs. 2020 Oct;20(5):413-418. doi: 10.1007/s40256-020-00429-7.
Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.
胺碘酮是最广泛开处方的抗心律失常药物之一，用于治疗室性和室上性心律失常，已被确定为一种候选药物，可用于对抗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。我们提出了在 COVID-19 情况下使用胺碘酮的基本原理，以及根据目前的证据，胺碘酮的给药是否代表了预防 SARS-CoV-2 感染的潜在策略，而不仅仅是用于治疗已经出现症状和/或患有严重 2019 年冠状病毒病（COVID-19）的患者。
